Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study

Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study

Abstract Background Despite the proven benefits of iron chelation therapy (ICT) in the management of chronic iron overload and related complications, compliance to long-term ICT is challenging. Results from the ECLIPSE study, an open-label, randomized, multicenter, 2-arm, phase 2 study evaluated the...

Full description

Bibliographic Details
Main Authors: Immacolata Tartaglione, Raffaella Origa, Antonis Kattamis, Michael Pfeilstöcker, Sibel Gunes, Susanne Crowe, Niamh Fagan, Beatrice Vincenzi, Giovan Battista Ruffo
Format: Article
Language:English
Published: BMC 2020-08-01
Series:Experimental Hematology & Oncology
Subjects:
Deferasirox
Chelation
Film-coated tablet
Iron overload
Long-term
Safety
Online Access:http://link.springer.com/article/10.1186/s40164-020-00174-2

Internet

http://link.springer.com/article/10.1186/s40164-020-00174-2

Similar Items